Introduction
Atherosclerotic cardiovascular disease (CVD) remains the leading cause of death in the US [1] and is now also the most common cause of death worldwide [2] . It is well established that atherosclerosis, the pathologic basis for CVD, begins in childhood and progresses into adulthood [3] . The major modifiable risk factors for CVD -smoking, hypertension, hypercholesterolemia, diabetes, and obesity -often begin in early life as well [4] . Several studies have found that the number of CVD risk factors present in individuals correlates with the severity of atherosclerosis in both children and young adults [5, 6, 7 ] . Abnormal cholesterol levels in particular are increasingly common in adolescents, affecting one in five youth aged 12-19 [8] , and are associated with atherosclerosis in adulthood [9] . This review will discuss CVD risk assessment and prevention in the adolescent population and will focus on cholesterol screening and management. Adolescence is a common time for the emergence of CVD risk factors as well as the establishment of behavior patterns that affect CVD development and progression. Obesity, tobacco use, diabetes, hypertension, and hypercholesterolemia are all increasingly common in adolescence and some authors have predicted that the US may see a reduction in life expectancy due to these trends [10] . However, estimating the lifetime risk of a cardiovascular event for young individuals remains difficult because traditional tools only estimate the risk of an event in the next decade [11 ] . Furthermore, guidelines for the identification and treatment of hypercholesterolemia, a major modifiable risk factor for CVD, differ for children and adults. Providers caring for adolescents need to be aware of these differences and be able to provide comprehensive cardiovascular risk assessment for this population.
Since Kohn and Jacobson's [12] article on cardiovascular risk in adolescents was published in this journal in 2004, there have been revisions of both the pediatric and adult cholesterol screening and treatment guidelines [13, 14] . In addition, there have been advancements and new controversies regarding the assessment of cardiovascular risk with novel biomarkers and imaging modalities [15 ] . This study will review the changes in recommendations for lipid management in adolescents as well as discussing the discrepancies between pediatric and adult guidelines. It will also highlight conditions and illnesses common in adolescence that affect both lipid levels and treatment goals. Finally, tools for assessing, preventing, and treating CVD risk factors in adolescents will be discussed.
Guidelines for the detection and treatment of hypercholesterolemia in adolescents
In 2008 the American Academy of Pediatrics (AAP) Committee on Nutrition issued the policy statement 'Lipid Screening and Cardiovascular Health in Childhood' [13] . These guidelines replaced those last issued in 1998 [16] and reflected emerging data from several cohort studies on cumulative cardiovascular risk from childhood into adulthood [5, 6, 17] . The 2008 guidelines expanded the indications for cholesterol screening, endorsed fasting lipid profiles for all individuals, reduced the age [and, in the case of those with diabetes, the low density lipoprotein (LDL) levels] at which pharmacologic intervention should be considered, and added several classes of acceptable lipid lowering medications. The expansion of pharmacologic options in particular sparked significant controversy within the pediatric and lay communities [18] .
The AAP policy statement refers providers treating patients older than 18 to the Adult Treatment Panel (ATP) guidelines from the National Cholesterol Education Program, although these are actually designed for individuals aged 20 and older. The ATPIII guidelines published in 2002 focus on the importance of LDLcholesterol to cardiovascular health and the modification of LDL-cholesterol according to overall risk of CVD [19] . An update of ATPIII was published in 2004, prompted by emerging trial data that supported the lowering of LDLcholesterol even further for adults at moderate to high risk of CVD [14] . These lower LDL goals will likely be incorporated into the ATPIV recommendations due for release in 2010.
Providers caring for older adolescents and young adults need to understand the differences between the pediatric and adult guidelines (Table 1) and be able to apply both as their patients age. Key areas of difference are the screening interval, the LDL treatment goals, and the use of CVD risk projection to alter those treatment goals. Notably the guidelines recommend more frequent lipid screening in adolescents as compared with adults but a higher LDL level at which to begin treatment. Whereas elevated cholesterol levels in adolescence are known to track into adulthood, their sensitivity and specificity for elevated cholesterol levels in adulthood remain low at around 40 and 80%, respectively [20] . This corresponds to high false-negative rates, which can be partially addressed by more frequent screening, and high false-positive rates, which can be addressed by higher thresholds for treatment [21] .
Cholesterol screening in adolescence is particularly challenging for several reasons. First, there are significant changes in lipid concentrations during puberty [22 ] . HDL levels decline in males throughout puberty, whereas total and LDL-cholesterol decline in early puberty but rise again as males approach adulthood. In contrast, total and LDL-cholesterol rise throughout puberty in females, whereas HDL levels stay essentially the same. Second, adolescents often present to clinic unaccompanied and may be unaware of a family history of elevated cholesterol. Finally, adolescents may be unlikely to return for fasting lipid profiles, currently the screening test recommended by the AAP. Fortunately, a recent study in adults found nonfasting total and HDLcholesterol were as strongly associated with CVD as fasting levels or directly measured LDL-cholesterol [23 ] . Given these findings, we recommend obtaining a nonfasting total and HDL-cholesterol for all adolescents with risk factors or unknown family history, preferably before the onset of puberty or, if not, in late adolescence. If the initial nonfasting levels are elevated, a fasting lipid panel should be pursued. All patients should have a screening total and HDL-cholesterol assessment by the age of 20.
Special populations and considerations
The 2008 AAP recommendations are targeted to all children and adolescents, but special consideration is necessary for patients with other conditions associated with accelerated atherosclerosis. Whereas most practitioners are aware of the increased risk for CVD in patients with familial hypercholesterolemia, they may be less familiar with the risk incurred by diabetes mellitus, chronic kidney disease, chronic inflammatory diseases, congenital heart disease, and childhood cancer survivorship. In 2006 the American Heart Association released a scientific statement endorsed by the AAP defining the increased risk for CVD in these groups and recommending comprehensive cardiovascular assessment and treatment strategies for those affected by these Cholesterol management in adolescent population Gooding and de Ferranti 399 conditions ( Table 2) [24] . Conditions are divided into those conferring the highest risk (tier I), a moderately increased risk (tier II), or an increased risk (tier III) for CVD. Patients with tier II or III conditions who have two or more additional cardiovascular risk factors should be treated to the goals of the lower tier. This is consistent with the adult guidelines' recommendation for alteration of lipid goals based on the number of cardiovascular risk factors present [19] .
In addition to these relatively uncommon conditions which accelerate atherosclerosis, providers need to be aware of common adolescent conditions which can alter lipid levels and cause secondary dyslipidemia (see below).
(1) Hypothyroidism (2) Anorexia nervosa (3) Drugs (estrogens, progestins, anabolic steroids, corticosteroids, protease inhibitors, oral retinoids) (4) Alcohol (5) Diabetes mellitus (6) Chronic renal failure or nephrotic syndrome (7) Liver failure Hypothyroidism, both subclinical and overt, is associated with increases in total and LDL-cholesterol and decreases in HDL-cholesterol due to alteration in liver metabolism of these molecules [25] . Screening for thyroid dysfunction with a thyroid stimulating hormone is recommended for all patients with dyslipidemia by the adult guidelines [19] , and, although it is not mentioned in the pediatric guidelines, it is a reasonable approach in adolescents. Treatment with thyroxine improves lipid panels and is recommended for overt hypothyroidism but debated for those with subclinical disease. Anorexia nervosa, another illness commonly presenting in this age group, is also associated with increased total and LDLcholesterol. This is likely due to the presence of excess cortisol, reduced free thyroxine, and increased lipolysis seen in these patients [26] . Weight gain has been demonstrated to normalize the cholesterol abnormalities seen in patients with anorexia [27] .
Medications used by adolescents are also associated with alterations in the lipid profile. The most common are oral contraceptive pills (OCPs) and injectable contraceptives, which have shown mixed effects [28 ] . In general estrogens increase triglycerides and HDL-cholesterol while lowering LDL-cholesterol, whereas progestins have the opposite effect. The advent of less androgenic progestins has lessened the rise in LDL-cholesterol seen in earlier OCP formulations but the overall net effect continues to be a slight rise in all aspects of the lipid panel [29 ] . Although not as commonly prescribed as OCPs, there is increasing use of atypical antipsychotics to treat adolescents with bipolar disease and psychotic disorders, and olanzapine and clozapine in particular can cause significant increases in triglyceride levels independent of their associated weight gain [30 ] . It is helpful to get a baseline lipid assessment before starting either OCPs or antipsychotics in adolescents. If a change in the lipid profile is detected after the initiation of drug therapy, the magnitude and risk of the increase must be weighed against the necessity of the drug. Finally, alcohol can raise both HDL-cholesterol and triglycerides [31] and excess use or binge drinking should be considered in adolescents with isolated hypertriglyceridemia.
Treatment
Lifestyle modification is the mainstay of treatment for adolescents with CVD risk factors. The most recent American Heart Association guidelines recommend all teens eat fruits and vegetables daily, use whole-grain breads and nonfat or low-fat milk products, reduce their intake of sugar-sweetened beverages and salt, prepare foods with vegetable oils and margarines low in saturated fats, and eat minimal to no trans-fats [32] . Adolescents with elevated lipid levels should adhere to a diet that restricts saturated fat to 7% of total calories and dietary cholesterol to 200 mg per day and that includes supplemental fiber at a dose of the patient's age plus 5 g per day, or 20 g per day for those over age 15. The safety and efficacy of these recommendations was established by the Dietary Intervention Study in Children (DISC), which found a 4.8 mg/dl reduction in LDL after 1 year in children randomized to a low-fat diet and found no difference relative to controls with respect to height or sexual maturation over 7 years of follow-up [33] . Physical activity should also be increased to 60 min per day and weight reduced if the adolescent is overweight or obese. Motivational interviewing techniques may be helpful when counseling adolescents regarding lifestyle change [34 ] . All of these recommendations are consistent with adult guidelines for those patients over age 18 [19] .
For adolescents who do not meet their LDL goal through a trial of therapeutic lifestyle changes (TLCs), pharmacologic treatment is warranted, although adherence can be a challenge in this population [35 ] . Whereas the pediatric guidelines do not define the time for trial of TLC, 6 months is a reasonable trial with an extension if the patient is having some success. Adolescents were historically treated with bile acid binding resins, but up to 50% of teens studied stopped the drugs due to poor palatability and gastrointestinal side effects [36] . The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are now arguably the first-line treatment in adolescents with elevated LDL-cholesterol. Multiple trials have demonstrated the safety and efficacy of statins in adolescents [37] and the most recent pediatric guidelines recommend their use in children as young as 8 years of age [13] . Importantly, growth and pubertal maturation do not appear to be affected by statin use [38] , although subtle effects cannot be excluded by the current published data. Although there is emerging data on the use of ezetimibe in this population [39 ] , its efficacy has recently been questioned in adults [40] and therefore statins remain the preferred drug for elevated LDL. All adolescent females should be counseled on the teratogenic effects of statins and their contraindication in pregnancy, and appropriate birth control methods should be used for sexually active teens. Given the rare side effects of hepatic toxicity and rhabdomyolysis, the American Heart Association recommends baseline measurement of creatine kinase, alanine aminotransferase and aspartate aminotransferase before initiation of statin therapy [37] . Our practice is to measure efficacy and side effects initially monthly and then every 6 months. It is important to note that, whereas the efficacy of statins for preventing first cardiovascular events is well established in adults [41] , the same is not true for the adolescent population. However, trials that would support such an assertion are unlikely to be performed, given the large sample size and long followup necessary.
Cholesterol management in adolescent population Gooding and de Ferranti 401 Treatment goals for elevated triglycerides and low HDL are not well defined in the pediatric guidelines [13] . Physical activity and weight reduction have been shown to increase HDL by 20-30% in adults and are recommended by the adult guidelines for patients with an HDL below 40 mg/dl [19] . Drug therapy for an isolated low HDL in adults is controversial and is not recommended for younger patients. Similarly, the adult guidelines [19] suggest TLC as the primary therapy for triglycerides in the borderline (150-199 mg/dl) and high (200-499 mg/dl) range. Drug therapy with either a statin if the patient's LDL is not at goal or a fibrate or nicotinic acid if the LDL is at goal may be considered for adults with high triglycerides that do not improve with TLC. Initiating triglyceridelowering therapy with a fibrate is suggested for very high levels (>500 mg/dl) to prevent triglyceride-associated pancreatitis. It is reasonable to apply these guidelines to adolescents, and fibrates have been well tolerated by adolescents in at least one study [42] . However, nicotinic acid is not recommended in this age group due to its high adverse event rate and bothersome cutaneous flushing [43] . Dietary changes and physical activity have been shown to benefit adolescents with high triglycerides and low HDL [44, 45] and remain the mainstay of treatment for these lipid abnormalities in both children and adults.
A recent survey by the Centers for Disease Control found 16% of adolescents use complementary or alternative therapies [46] and patients may inquire about those advertised to promote cardiovascular health. There are some data for the ability of naturally occurring substances such as plant sterols [47] , omega-3 and omega-6 fatty acids [48 ] , soy products [49] , and red rice yeast [50 ] , but not garlic [51] , to lower cholesterol and cardiovascular risk. At least one study in adults found a similar level of LDL reduction to statins in those treated with multiple alternative therapies at once [52] . Whereas few of these studies have been done in adolescents, the products are generally well tolerated. Such complementary therapies can be used in adjunct with TLC or in adolescents with borderline cholesterol levels, but should not replace pharmacologic treatment with statins or bile acid resins for those teens at greatest cardiovascular risk.
New directions in cardiovascular risk assessment
Elevated cholesterol is only one risk factor for cardiovascular disease. Comprehensive CVD risk assessment includes annual assessment of blood pressure, body mass index (BMI), tobacco use and family history of CVD as well as screening for diabetes when indicated. The Pathological Determinants of Atherosclerosis in Youth (PDAY) group has created a cardiovascular risk score comprised of these various risk factors for adolescents and young adults [53] . Although not in clinical use at present, the PDAY offers an interesting new possibility for assessing lifetime risk of CVD in youth. Noninvasive markers of atherosclerosis such as ultrasonography of carotid intima-medial thickness (CIMT) and computed tomography of coronary artery calcification (CAC) are also used in research settings with adolescents [54] . Whereas both have been associated with actual CVD outcomes in adults [55] , a recent US Preventive Services Task Force review concluded there was insufficient evidence to endorse the use of either of these modalities over traditional risk factor assessment in adults [15 ] . C-reactive protein (CRP) has also received considerable attention in the adult CVD literature [56 ] and does appear to add additional information beyond traditional risk factor assessment in adults [15 ] . The association between high CRP in youth and atherosclerosis in adulthood is less clear [57, 58] and CRP does not appear to be as tightly correlated with CVD risk factors other than obesity in this age group [59] . Measurement of CRP in adolescents for the purpose of CVD assessment is not currently recommended outside the research arena, given the general lack of data at this time. The soundest evidence in both adolescents and adults remains for comprehensive cardiovascular risk assessment based on the traditional risk factors of age, sex, family history, BMI, blood pressure, cholesterol, and glucose.
Conclusion
Atherosclerosis begins in childhood. Adolescence presents a prime opportunity to assess risk factors for CVD and to intervene to prevent its development. Comprehensive cardiovascular risk assessment includes inquiry regarding family history and tobacco use along with measurement of BMI and blood pressure. Lipid profiles should be obtained in adolescents with a positive or unknown family history or with any other CVD risk factors, including obesity, and in all patients by the age of 20. Clinicians caring for adolescents should be aware of new recommendations from the American Academy of Pediatrics and the Adult Treatment Panel of the National Cholesterol Education Program and be able to apply both as patients transition to adulthood. Adolescents with diabetes, chronic inflammatory diseases, a history of childhood cancer, or congenital or acquired heart disease require special consideration and more aggressive cardiovascular risk management. Several conditions common in adolescence, including the use of alcohol or combined hormonal contraception and thyroid and eating disorders, can also affect lipid levels and cardiovascular risk. Clinicians should be able to counsel all patients regarding lifestyle modifications to prevent CVD and use pharmacologic treatment when necessary to improve lipid profiles. Early identification and intervention in childhood and adolescence is necessary to prevent morbidity and mortality from the lifetime risk of cardiovascular disease in adulthood.
